Navigation Links
New approach to Alzheimer's therapy
Date:7/30/2010

The brains of Alzheimer patients have high accumulations of the material beta-amyloid, which appear in the form of plaques. The precursors of these plaques are believed to be the underlying cause of the nerve cell loss that leads to the disruptions in memory that characterize Alzheimer's disease. The main aim of many Alzheimer therapies is therefore to inhibit the formation of beta-amyloid. Since beta-amyloid is cleaved from the so-called amyloid precursor protein (APP), scientists have focused on stopping the two enzymes that attack the precursor protein. These act like molecular scissors and cut out the beta-amyloid fragment. Blocking these scissors precludes the formation of beta-amyloid.

DZNE and LMU researchers have succeeded in identifying an enzyme known as alpha secretase, which cleaves the amyloid precursor protein (APP) without forming beta-amyloid. Up to this point three different candidates for this function had been under consideration, but the research team has now been able to show that the enzyme ADAM10 alone is responsible for the specific cleavage. Dr. Stefan Lichtenthaler and his team developed highly specific antibodies that can identify the different cleavage products of the precursor protein in the brain cells of mice and in human cell cultures. Using a special technique called RNA interference, the researchers managed to block each of the three genes that code for the three ADAM enzymes under suspicion. An analysis of the cleavage products revealed that the ADAM10 gene was the only one able to prevent the formation of beta-amyloids. They confirmed their results using mass spectrometry.

"In ADAM10 we have identified a target molecule that plays a central role in the development of the molecular processes in Alzheimer's disease. We know that ADAM10 is less active in Alzheimer patients," says Dr. Lichtenthaler. When ADAM10 is less active, the precursor protein is more likely to be cleaved in a way that promotes the formatio
'/>"/>

Contact: Sonja Juelich-Abbas
sonja.juelich-abbas@dzne.de
49-228-433-02260
Helmholtz Association of German Research Centres
Source:Eurekalert

Page: 1 2

Related biology news :

1. Discovery points to new approach for diabetes therapy
2. Personalized approach to smoking cessation may be reality in 3-5 years
3. Stem-cell therapy may provide new approach to fight infection
4. Insight into cells could lead to new approach to medicines
5. Entrust Credentialing Services - A New End-to-End, SAAS Approach for Identity-Based Smartcards
6. No more pills: Male contraceptive takes new approach
7. Epigenetic concepts offer new approach to degenerative disease
8. Dual approach gives a more accurate picture of the autistic brain
9. Development of new anti-cancer gene therapy approach using lentiviral vectors
10. Asexual plant reproduction may seed new approach for agriculture
11. Preventing or reversing inflammation after heart attack, stroke may require 2-pronged approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... in the rugged Marquesas Islands (French Polynesia) have increased the ... research and collecting in conjunction with the Vascular Flora ... Polynesie franaise projects have yielded 62 new species of ... 360, of which 18 are newly described and illustrated in ...
... available in German . They live their lives upside ... position, sloths spend most of their lives hanging in trees upside ... Very slowly. But why are sloths so ,lazy,? And how has ... in the course of evolution? Zoologists of the Friedrich Schiller University ...
... to be genes that, when mutated, change healthy cells into ... of the University of Southern California (USC) have proven that ... paving the way to a safer and more practical approach ... cell therapy. "The reality may be more complicated than ...
Cached Biology News:Marquesas Islands in French Polynesia yield 18 new species of rare ferns and flowering plants 2The decoding of slowness 2USC research: Cancer cells and stem cells share same origin 2
(Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/19/2014)... December 19, 2014 Charm Sciences is ... for the Detection of Aflatoxin M1 in raw commingled ... independent third party validation. The peer reviewed report of ... the Institute for Agricultural and Fisheries Research (ILVO-T&V) has ... , Aflatoxin B1, the most toxic aflatoxin and a ...
(Date:12/19/2014)... 19, 2014 Bina Technologies, Inc. (Bina, ... they have been acquired by Roche (SIX: RO, ROG; ... held company that provides a big data platform for ... data for the academic and translational research markets.  Bina ... will continue to focus on development of their innovative ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) today reported the ... August 31, 2008. All dollar amounts referenced,herein are in ... 2008, our cash and cash equivalents totaled $9.8 million,compared ... net loss for the third quarter of 2008 was ...
... 15 Quincy Bioscience (Madison, WI),announces that ... of the jellyfish protein apoaequorin, has displayed ... subjects tested. The Prevagen,Memory Study included 56 ... mg/day). The findings suggest that supplementation with,apoaequorin, ...
... 08/07 ... millions sales change millions sales change, ... 16 Other EU countries (2) 7.1 24 17 8.6 ... 24 1.8 5 18, SLIT ...
Cached Biology Technology:Vasogen Announces Third Quarter 2008 Results 2Vasogen Announces Third Quarter 2008 Results 3Vasogen Announces Third Quarter 2008 Results 4Vasogen Announces Third Quarter 2008 Results 5Vasogen Announces Third Quarter 2008 Results 6Vasogen Announces Third Quarter 2008 Results 7Vasogen Announces Third Quarter 2008 Results 8Vasogen Announces Third Quarter 2008 Results 9Vasogen Announces Third Quarter 2008 Results 10Jellyfish Protein Shows Potential to Help With Memory 2Jellyfish Protein Shows Potential to Help With Memory 3Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14% 2Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14% 3
... Partek Genomics Solution is a comprehensive ... data visualization specifically designed to reliably ... for high-dimensional genomic studies containing thousands ... fast, memory efficient and will analyze ...
Kit contains: Bio-Rad Amplification Reagent, 2x Amplification Diluent, Streptavidin-HRP, Blocking Reagent, and Phosphate Buffered Saline....
These macrocarriers are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 macrocarriers....
Intestinal Epithelium Differentiation Environment...
Biology Products: